Matthew Eaton, Ph.D., is the VP of Computational Biology & Bioinformatics at Precede Biosciences, where he leads the development of cell-free epigenomic biomarker discovery and diagnostic platforms. With over 20 years of experience at the intersection of computational biology and multi-omics analysis, Matthew has spent more than a decade leading computational teams in the biotechnology industry. His background includes deep expertise in investigating the intersection of human disease with genetics, epigenetics, chromatin, and gene expression.
Previously, as Head of Computational Biology at Syros Pharmaceuticals, he helped establish a platform based on epigenomics to discover new targets for drug development, leading cross-functional teams in both discovery and clinical translational efforts. Matthew completed his postdoctoral research at MIT and the Broad Institute, focusing on the computational analysis of chromatin and human variation. He holds a Ph.D. in Computational Biology and Bioinformatics from Duke University and a B.A. in Computer Science and Philosophy from Wesleyan University.
Matthew is personally driven to advance the mission of the CSNK2A1 Foundation as the father of a daughter with Okur-Chung Neurodevelopmental Syndrome. He is eager to leverage his experience in genomic research and drug discovery to help accelerate the search for treatments and a cure.